Biocon settles Roche's US patent lawsuit over proposed breast — cancer drug copy

By Blake Brittain Oct 14 (Reuters) — Roche's Genentech has settled a US lawsuit against Indian biopharmaceutical company Biocon over its proposed biosimilar of Genentech's blockbuster breast-cancer drug Perjeta, Biocon said Wednesday. Biocon said in a statement that the settlement gives it the "earliest licensed launch dates" for a Perjeta biosimilar, allowing the company to launch its Pebrilzo in the first quarter of 2027 in the UK and European Union, and the third quarter of 2028 in the United States The release said that other terms of the agreement are confidential Biosimilars are versions of biologic drugs ​that are comparable to generics of traditional pharmaceuticals. Unlike ‌traditional ⁠drugs, complex biologic drugs are made from living cells and cannot be copied exactly Genentech's biologic Perjeta was Switzerland-based Roche's sixth-best-selling ​drug last year, ​earning ⁠it nearly CHF 2.97 billion ($3.67 billion) in revenue worldwide, according to a ​company report Genentech sued Biocon in New Jersey earlier this year, alleging Biocon's biosimilar would infringe its patents The court dismissed the lawsuit on Wednesday at Genentech's request Biocon did not respond to Gen